- Home
- A Review of Emerging ARNI Data in HFrEF
A Review of Emerging ARNI Data in HFrEF
- Heart Failure
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.
Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.
Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.
This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
Support Statement
This activity has been supported by an unrestricted educational grant from Novartis.
Disclosure
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
1. Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
2. Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- Heart Failure Specialists
- General Cardiologists
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
- understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
- interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
- apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
- Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| 1 | Welcome and Introduction | Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 2 | ARIADNE in Review | Uwe Zeymer (Klinikum Ludwigshafen, DE) | |
| 3 | Commentary on the ARIADNE Trial | Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 4 | PROVE-HF in Review | James L Januzzi (Harvard Medical School, MA, US) | |
| 5 | EVALUATE-HF in Review | Akshay S Desai (Harvard Medical School, MA, US) | |
| 6 | Commentary on the PROVE-HF and the EVALUATE-HF Trials | Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 7 | TRANSITION-CHF in Review | Rolf Wachter (Universität Leipzig, Leipzig, DE) | |
| 8 | PIONEER in Review | David Morrow (Harvard Medical School, MA, US) | |
| 9 | Commentary on the TRANSITION-CHF and the PIONEER Trials | Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) | |
| 10 | Conclusions | Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US) |
Welcome and Introduction
Duration:
Speakers: Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Commentary on the ARIADNE Trial
Duration:
Speakers: Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Commentary on the PROVE-HF and the EVALUATE-HF Trials
Duration:
Speakers: Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Commentary on the TRANSITION-CHF and the PIONEER Trials
Duration:
Speakers: Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Conclusions
Duration:
Speakers: Andrew JS Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)
Course Director
Speaker
The event ‘A Review of Emerging ARNI Data in HFrEF’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Related Courses
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- 1.00
Published:
Learning objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1.00
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
- Not accredited
Published:
Learning objectives
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF